奥沙利铂治疗原发性肝癌的临床效果

Clinical effect of oxaliplatin in the treatment of primary liver cancer

目的探讨原发性肝癌患者采用奥沙利铂进行化疗治疗的临床效果。方法选取本院2017年8月至2018年8月收治的原发性肝癌患者66例,按照随机数字表方法分为两组,每组33例。对照组采用吉西他滨联合顺铂治疗,观察组采用吉西他滨联合奥沙利铂治疗,对比两组患者治疗的临床效果。结果观察组和对照组治疗的有效率分别为54.55%和45.45%,两组比较差异有统计学意义(P<0.05);治疗前,两组患者的肝功能以及甲胎蛋白水平相比差异无统计学意义,治疗后,两组患者的肝功能以及甲胎蛋白水平均明显降低,且观察组明显优于对照组(P<0.05),两组比较差异有统计学意义;观察组不良反应发生率为48.48%,明显低于对照组的69.70%,两组比较差异有统计学意义(P<0.05)。结论对原发性肝癌患者采用奥沙利铂进行化疗治疗,有利于提高治疗效果,延长患者的生存期限,临床应用价值较高,值得临床推广。

Objective To explore the clinical effect of oxaliplatin chemotherapy in patients with primary liver cancer. Methods 66 patients with primary liver cancer treated in our hospital from August 2017 to August 2018 were selected and they were divided into two groups according to the random number table method, with 33 patients in each group. The control group was treated with gemcitabine and cisplatin, and the observation group was treated with gemcitabine and oxaliplatin. The clinical effects of the two groups were compared. Results The effective rates of treatment in the observation group and the control group were 54.55% and 45.45%, respectively. The difference between the two groups was statistically significant(P<0.05). Before treatment, there was no statistically significant difference in liver function and alpha-fetoprotein levels between the two groups of patients. After treatment, liver function and alpha-fetoprotein levels of the two groups of patients were significantly reduced, and the observation group was significantly better than the control group(P<0.05). The difference between the two groups was statistically significant;adverse reactions occurred in the observation group. The rate was 48.48%, which was significantly lower than 69.70% in the control group. The difference was statistically significant between the two groups(P<0.05). Conclusion The use of oxaliplatin for chemotherapy in patients with primary liver cancer is beneficial to improve the treatment effect and prolong the survival time of patients. It has higher clinical application value and is worthy of clinical promotion.